摘要The inauguration of the National Registration and Accreditation Scheme (NRAS) in July 2012 marked a significant milestone in the history of Chinese medicine (CM) in Australia.Although it has been a recent achievement,it has been made possible because of the hard work and dedication of many individuals and organizations over the past years.1 The positive impacts experienced throughout the legislative process have grown within economics,education,and culture.However,it is important to note that there are problems concerning CM education,standardization and scientization,and CM products themselves,which will impede further development of CM worldwide.To address these problems,in this paper,we put forward eight constructive suggestions from both government and pharmaceutical corporations' points of view,and firmly states that a convergence between CM and mainstream medicines will greatly benefit human healthcare in the foreseeable future.